Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteria
Takuya Sho(Hokkaido University), Naoya Sakamoto(Chibaken Saiseikai Narashino Hospital), Masatsugu Ohara(Hokkaido University), Masaru Baba(Hokkaido hospital), Mitsuteru Natsuizaka(Sapporo University), Masato Nakai(Hokkaido University), Katsumi Terasita(Hokkaido hospital), Jun Ito(Kobe University), Taku Shigesawa(Hokkaido University), Koji Ogawa(The Japanese Society of Gastroenterological Surgery), Tomofumi Takagi(Hokkaido hospital), Kenichi Morikawa(Hokkaido University), Toshiya Kamiyama(Hokkaido University), Akinobu Taketomi(Hokkaido University), Ken Furuya(Hokkaido hospital), Machiko Umemura(Hokkaido University), Yoshiya Yamamoto, Akihisa Nakamura(Hokkaido University), Kazuharu Suzuki(Hokkaido University), Tomoe Kobayashi(Shigei Medical Research Institute), Takuto Miyagishima(Kushiro Rosai Hospital), Naoki Kawagishi(Hokkaido University), Takashi Meguro(Hokkaido hospital), Goki Suda(Sapporo University)
Cited by 44
Related Papers
Evidence-based clinical practice guidelines for Liver Cirrhosis 2020
|Journal of Gastroenterology|2021|424
Meflin-Positive Cancer-Associated Fibroblasts Inhibit Pancreatic Carcinogenesis
|Cancer Research|2019|328
Interleukin‐6/<scp>STAT</scp>3 signaling as a promising target to improve the efficacy of cancer immunotherapy
|Cancer Science|2017|295
Genome-wide Association Study Identifies TNFSF15 and POU2AF1 as Susceptibility Loci for Primary Biliary Cirrhosis in the Japanese Population
|The American Journal of Human Genetics|2012|272
Long‐term and perioperative outcomes of laparoscopic versus open liver resection for hepatocellular carcinoma with propensity score matching: a multi‐institutional Japanese study
|Journal of Hepato-Biliary-Pancreatic Sciences|2015|267